Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by investment analysts at JPMorgan Chase & Co. from $168.00 to $200.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 20.45% from the stock’s previous close.

ASND has been the topic of several other reports. Evercore ISI upped their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target on the stock. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, The Goldman Sachs Group increased their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Price Performance

ASND opened at $166.05 on Tuesday. The company has a market capitalization of $10.08 billion, a P/E ratio of -23.39 and a beta of 0.62. The firm’s fifty day moving average price is $140.06 and its two-hundred day moving average price is $135.30. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. On average, equities research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Ascendis Pharma A/S in the fourth quarter valued at about $28,000. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $30,000. Jones Financial Companies Lllp boosted its stake in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 197 shares during the last quarter. Blue Trust Inc. grew its position in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after buying an additional 328 shares during the period. Finally, Groupama Asset Managment acquired a new position in Ascendis Pharma A/S in the third quarter valued at approximately $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.